Womens Health

GLP-1 Medications and Fertility: What You Need to Know Before Conceiving

If you're taking a GLP-1 medication like semaglutide or tirzepatide and thinking about getting pregnant, you probably have questions. Can these medications affect your fertility? When should you stop taking them? And what about the weight loss benefits—could those actually help with conception?

The relationship between GLP-1 medications and fertility is more nuanced than a simple yes or no. Let's break down what we know, what the research shows, and how to approach pregnancy planning if you're currently on GLP-1 therapy.

Understanding GLP-1 Medications and Reproductive Health

GLP-1 receptor agonists work by mimicking a hormone your body naturally produces to regulate blood sugar and appetite. Medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have become increasingly popular for weight management and metabolic health.

Here's what matters for fertility: these medications haven't been extensively studied in pregnant women, and manufacturers recommend discontinuing them before trying to conceive. But the story doesn't end there.

How Weight Loss Can Actually Improve Fertility

One of the most important things to understand is that obesity itself can significantly impact fertility. For women, excess weight is associated with irregular ovulation, hormonal imbalances, and conditions like polycystic ovary syndrome (PCOS) that make conception more difficult.

When GLP-1 medications help you lose weight, they may indirectly improve your fertility by:

Many women have reported unexpected pregnancies after starting GLP-1 medications, often because their cycles became more regular as they lost weight. This is actually a sign that metabolic health and fertility are closely connected.

Current Recommendations for Pregnancy Planning

The official guidance from medication manufacturers is clear: stop taking GLP-1 medications at least two months before trying to conceive. For semaglutide specifically, the recommendation is to discontinue the medication at least two months prior to a planned pregnancy due to its long half-life.

This washout period allows the medication to clear your system before conception. While we don't have evidence of harm, we also don't have enough data to confirm safety during early pregnancy, so the precautionary approach makes sense.

What If You Get Pregnant While Taking GLP-1s?

First, don't panic. Contact your healthcare provider right away and stop taking the medication. While GLP-1 medications aren't recommended during pregnancy, accidental exposure in very early pregnancy doesn't automatically mean there will be problems.

Your doctor will want to monitor your pregnancy more closely and may recommend additional ultrasounds or testing. Be honest with your prenatal care team about your medication history so they can provide the best care.

For Women: Special Considerations

If you're a woman of childbearing age taking GLP-1 medications, fertility awareness is crucial. The weight loss these medications provide can make birth control pills less effective in some cases, and as mentioned, restoring metabolic health may make you more fertile than you've been in years.

Consider these steps:

What About Men and Fertility?

The research on GLP-1 medications and male fertility is even more limited than for women. Currently, there's no official recommendation for men to stop these medications before attempting to conceive with a partner.

That said, obesity in men is associated with lower testosterone levels, reduced sperm quality, and decreased fertility. Weight loss achieved through GLP-1 therapy may actually improve male fertility markers by:

If you're a man concerned about fertility while on GLP-1 medications, discuss your specific situation with your doctor. They may recommend a semen analysis or other testing to assess your reproductive health.

PCOS and GLP-1 Medications

For women with PCOS, GLP-1 medications deserve special mention. PCOS is one of the leading causes of infertility in women, and it's closely tied to insulin resistance and metabolic dysfunction.

Some research suggests that GLP-1 medications may help women with PCOS by improving insulin sensitivity, promoting weight loss, and potentially restoring ovulation. However, if you're actively trying to conceive, you'll need to work closely with a reproductive endocrinologist to time when to stop the medication and possibly transition to other PCOS treatments that are safer during conception attempts.

Balancing Weight Loss Goals and Family Planning

One of the trickiest aspects of GLP-1 therapy and fertility is timing. Many people want to reach their weight loss goals before getting pregnant, but they also don't want to delay family planning indefinitely.

Here's a realistic approach: work with your healthcare team to set a reasonable timeline. If pregnancy is in your near future (within 6-12 months), you might focus on moderate weight loss and metabolic improvements rather than waiting to hit a specific number on the scale.

Remember that even modest weight loss—around 5-10% of body weight—can significantly improve fertility outcomes. You don't need to reach your ideal weight before conceiving, especially if time is a factor in your family planning.

From the Ozari Care Team

If you're considering pregnancy while on GLP-1 therapy, start the conversation with your healthcare provider sooner rather than later. We recommend stopping these medications at least two months before trying to conceive, but we also encourage you to maintain the healthy habits you've built—the lifestyle changes matter just as much as the medication itself. Your metabolic improvements can continue to support your fertility even after stopping treatment.

At Ozari Health we offer compounded Semaglutide and Tirzepatide starting at $99/month prescribed by licensed physicians and shipped to your door. Learn more at ozarihealth.com.

Medically reviewed by the Ozari Clinical Care Team licensed physicians specializing in metabolic health and GLP-1 therapy. Last reviewed: April 25, 2026